30-month follow-up analysis of a RCT | Pembrolizumab vs. placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma.
5 Sep, 2022 | 14:20h | UTCInvited Commentary: Adjuvant immunotherapy for renal cell carcinoma – The Lancet Oncology
Original Article: Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma – New England Journal of Medicine